June 29, 2020 / 11:04 AM / 6 days ago

BRIEF-Tonix Announces Enrollment Of Phase 3 Relief Trial Of Tnx-102 Sl For Management Of Fibromyalgia Is Ahead Of Schedule

June 29 (Reuters) - Tonix Pharmaceuticals Holding Corp :

* TONIX PHARMACEUTICALS ANNOUNCES ENROLLMENT OF PHASE 3 RELIEF TRIAL OF TNX-102 SL FOR MANAGEMENT OF FIBROMYALGIA IS AHEAD OF SCHEDULE

* TONIX PHARMACEUTICALS HOLDING CORP - COMPANY ANTICIPATES TOPLINE PHASE 3 RELIEF RESULTS IN Q4 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below